Opioid Use Disorder: Braeburn’s New Drug Application (NDA) for BRIXADI™ (CAM2038), our extended-release buprenorphine medication developed for subcutaneous weekly and monthly dosing, has received Tentative Approval from FDA. Learn more about BRIXADI’s clinical trial results and Tentative Approval here.
Chronic Pain: Braeburn is also investigating CAM2038 in opioid tolerant patients with chronic pain as part of its ongoing pivotal Phase III program. Learn more about CAM2038’s clinical trial results here.
Watch the video above for a description of FluidCrystal® Injection Depot Technology. FluidCrystal® Injection Depot Technology is developed by Camurus.
Braeburn seeks to support innovations in the treatment of opioid use disorder, chronic pain and other related diseases. If you are interested in support from Braeburn to conduct your IIT, please email IITProgram@braeburnrx.com to request Braeburn’s IIT Guidelines. In general, Braeburn supports research based in the U.S. by experienced researchers in the fields of opioid use disorder and chronic pain. Please address any questions regarding Braeburn’s IIT Program to IITProgram@braeburnrx.com.